Coya Therapeutics presents oxidative stress biomarker data from ALS patients at the Society of Neuroimmune Pharmacology Conference in March 2024.

Coya Therapeutics, a clinical-stage biotech firm, is presenting data on an oxidative stress biomarker candidate from a large cohort of ALS patients at the Society of Neuroimmune Pharmacology Conference on March 10-13, 2024. Dr. Stanley Appel, M.D., Chairman of Coya's Scientific Advisory Board, will discuss the findings on March 12th. Coya is developing biologics to enhance regulatory T cell (Treg) function, with a focus on neurodegenerative diseases like ALS.